{"id":"high-dose-car-t-cells-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAR-T cell therapy involves extracting a patient's T cells, genetically modifying them to express a chimeric antigen receptor (CAR) that targets tumor-associated antigens, and reinfusing the expanded cells at high doses to mount a potent anti-tumor immune response. The high-dose approach aims to maximize therapeutic efficacy by increasing the number of tumor-targeting cells available to attack malignant cells.","oneSentence":"High-dose CAR-T cells are engineered immune cells that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:16.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (specific indication not detailed in available information)"}]},"trialDetails":[{"nctId":"NCT07350863","phase":"PHASE1","title":"U69-CART-Cells For R/R T-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-25","conditions":"Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT06875063","phase":"PHASE1","title":"GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-04-30","conditions":"Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell","enrollment":45},{"nctId":"NCT06285825","phase":"PHASE2","title":"A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-05","conditions":"Cytopenia","enrollment":32},{"nctId":"NCT06222853","phase":"PHASE1","title":"Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-02-10","conditions":"Systemic Lupus Erythematosus, CAR-T Cell Therapy","enrollment":22},{"nctId":"NCT05773040","phase":"PHASE1","title":"A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-14","conditions":"Lymphomas, B-cell Lymphomas","enrollment":33},{"nctId":"NCT06248086","phase":"PHASE1","title":"A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-09-06","conditions":"B-cell Lymphoma","enrollment":1},{"nctId":"NCT07106736","phase":"PHASE2","title":"MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-10","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":60},{"nctId":"NCT03635632","phase":"PHASE1","title":"C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2019-04-23","conditions":"Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma","enrollment":94},{"nctId":"NCT02663297","phase":"PHASE1","title":"Administration of T Lymphocytes for Prevention of Relapse of Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2016-06-07","conditions":"Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin","enrollment":18},{"nctId":"NCT06935136","phase":"NA","title":"Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-30","conditions":"CAR-T Cell Therapy, High-risk Large B-cell Lymphoma (LBCL)","enrollment":60},{"nctId":"NCT06918912","phase":"PHASE2","title":"Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure","status":"RECRUITING","sponsor":"Istituto Clinico Humanitas","startDate":"2023-06-16","conditions":"Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment","enrollment":50},{"nctId":"NCT06904131","phase":"NA","title":"A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors","status":"RECRUITING","sponsor":"Obstetrics & Gynecology Hospital of Fudan University","startDate":"2025-05-11","conditions":"Gynecological Solid Tumors","enrollment":20},{"nctId":"NCT06904729","phase":"PHASE3","title":"Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children","status":"RECRUITING","sponsor":"Guangzhou Women and Children's Medical Center","startDate":"2025-05-01","conditions":"Lupus Nephritis","enrollment":50},{"nctId":"NCT06758713","phase":"PHASE1","title":"Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Southern Medical University","startDate":"2025-01-15","conditions":"Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy","enrollment":60},{"nctId":"NCT06504199","phase":"PHASE2","title":"Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-07-18","conditions":"Mantle Cell Lymphoma","enrollment":39},{"nctId":"NCT06518876","phase":"PHASE1","title":"A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Novatim Immune Therapeutics (Zhejiang) Co., Ltd.","startDate":"2024-08-31","conditions":"POEMS Syndrome","enrollment":21},{"nctId":"NCT05700630","phase":"PHASE1","title":"Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-07-15","conditions":"HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency","enrollment":""},{"nctId":"NCT06223646","phase":"PHASE1, PHASE2","title":"A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Novatim Immune Therapeutics (Zhejiang) Co., Ltd.","startDate":"2024-01-11","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT04715217","phase":"PHASE1, PHASE2","title":"Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma","status":"UNKNOWN","sponsor":"Shanxi Province Cancer Hospital","startDate":"2021-01-04","conditions":"Lymphoma, B-Cell","enrollment":24},{"nctId":"NCT04714827","phase":"PHASE1, PHASE2","title":"Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanxi Province Cancer Hospital","startDate":"2021-01-22","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT05070156","phase":"EARLY_PHASE1","title":"B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tongji University","startDate":"2021-10-29","conditions":"Advanced Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT05749133","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM","status":"UNKNOWN","sponsor":"XuYan","startDate":"2023-04-10","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":18},{"nctId":"NCT04860817","phase":"EARLY_PHASE1","title":"A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL","status":"WITHDRAWN","sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","startDate":"2021-12-01","conditions":"T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT05445011","phase":"PHASE1","title":"Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-06-14","conditions":"Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT04823091","phase":"PHASE1","title":"Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-04-15","conditions":"T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT04796675","phase":"PHASE1","title":"Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-04-10","conditions":"Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin's Lymphoma","enrollment":27},{"nctId":"NCT04796688","phase":"PHASE1","title":"Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-03-10","conditions":"Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, B-cell Lymphoma","enrollment":27},{"nctId":"NCT04714593","phase":"PHASE1, PHASE2","title":"Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Shanxi Province Cancer Hospital","startDate":"2021-01-15","conditions":"Acute Lymphocytic Leukemia， B-Cell","enrollment":24},{"nctId":"NCT04162119","phase":"PHASE2","title":"Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2019-07-07","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT04163302","phase":"PHASE2","title":"Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2019-07-07","conditions":"Lymphoma, B-Cell","enrollment":30},{"nctId":"NCT03126864","phase":"PHASE1","title":"Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-04","conditions":"Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT04014881","phase":"PHASE1","title":"Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-07-06","conditions":"CD123+ Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT03642496","phase":"EARLY_PHASE1","title":"Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2018-08-19","conditions":"B-Cell Malignancies","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"High-dose CAR-T cells group","genericName":"High-dose CAR-T cells group","companyName":"Guangzhou Women and Children's Medical Center","companyId":"guangzhou-women-and-children-s-medical-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"High-dose CAR-T cells are engineered immune cells that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens. Used for Hematologic malignancies (specific indication not detailed in available information).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}